Skip to main content

Table 1 Summary of simulations: variables and levels

From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

Variable

Details and levels simulated

Vaccination: infant cohort (EPI cohort)

6, 10, 14 weeks; booster at 21 months

Vaccination: children cohort (5–17 months cohort)

Ages between 5–17 months first dose, and for 3rd dose 8–20 months; booster at 26–38 months

Model variants [8]

1. R0000 Base model

2. R0068 Heterogeneity in transmission: within-host variability

3. R0131 Immunity decay in effective cumulative exposure

4. R0132 Immunity decay in immune proxies

5. R0133 Immunity decay in both immune proxies and effective cumulative exposure

6. R0670 Heterogeneity in susceptibility to co-morbidity

EIR

0.1a, 1, 2, 4, 8, 16, 64, 256

Access to uncomplicated case management (%)b

0, 5, 40

Access inpatient care for severe cases (%)c

0, 100

Vaccination coveraged

0, 100

Initial efficacy against infection of third dose (%)

30, 60, 80, 100

Half-life (years)

0.5, 1, 3, 5

Initial efficacy against infection of boosting dose (%)e

Third dose efficacy, 30, 100

Weibull decay shape parameter (k)

k = 1 (exponential)

k = 0.5 (bi-phasic, quick decay followed by slow decay)

k = 3 (slow decay, followed by quick decay)

  1. aEIR of 0.1 was not simulated, predictions for this level are taken as 10 % of EIR 1
  2. bProbability of access to treatment for uncomplicated disease during a 5-day period (for mapping onto rates of access estimated from survey data see [6, 31]
  3. cProbability of access to hospital care (or equivalent) for severe disease during any 5-day period
  4. dFor each of the four delivery schedules
  5. eThis represents the absolute efficacy against infection achieved by the addition of a booster doses and not a percentage of the third dose